Medical research has confirmed that lung cancer occurs due to the accumulation of mutations in dozens of genes (including oncogenes and oncogenes, etc.) in the body, coupled with the stimulation of environmental carcinogenic factors. Certain genes in human body are closely related to the effects of targeted or chemotherapeutic drugs for lung cancer treatment. To test these specific genes, simply speaking, tumor cells or cancerous pleural fluid of the tested lung cancer patients are extracted and purified, and then genetic information is extracted and purified. At present, the efficiency of chemotherapy for lung cancer is still low, and many lung cancer patients did not benefit from chemotherapy drugs selected according to clinical experience in the past. Nowadays, lung cancer-related genetic tests, such as EGFR, KRAS, ALK, ERCC1 and RRM1, are performed on tumor biopsies or surgically resected tumor tissues and pathological specimens (KRAS mutation drugs include Androgel, ALK drugs include Crizotinib, etc.), and then which chemotherapy drug or molecular targeted therapy drug is selected according to the results of genetic tests, thus achieving individualized lung cancer treatment Targeted Therapy The reason why targeted therapy is called targeted is that these molecularly targeted drugs are designed to kill only tumor cells and avoid accidentally injuring normal tissue cells in the human body, and they are highly selective or precise according to specific molecular targets. Therefore, it is especially important to test for the corresponding gene status before choosing targeted drug therapy. Clinical studies have confirmed that patients with EGFR-sensitive mutations in non-small cell lung cancer who take EGFR-TKI targeted drugs such as Erysart, Troche or Kemena are more than ten times more effective than those without EGFR mutations. The targeted selection of molecular targeted drugs through lung cancer-related gene testing allows lung cancer patients with gene mutations to receive accurate and timely individualized treatment, while non-small cell lung cancer patients without EGFR gene mutations can avoid accompanying treatment or over-treatment. With the continuous development and clinical application of molecular targeted therapies, the treatment mode of more advanced non-small cell lung cancer patients has been converted to that of chronic lifestyle diseases, such as hypertension, diabetes and coronary heart disease, where lung cancer can be effectively controlled by taking drugs at home every day, making it possible for lung cancer patients to receive treatment with dignity and live with quality cancer, which we have been advocating and expecting. This makes it possible for lung cancer patients to receive treatment with dignity and live a quality life with cancer.